Literature DB >> 23200684

Egg banking in the United States: current status of commercially available cryopreserved oocytes.

Alexander M Quaas1, Alexander Melamed, Karine Chung, Kristin A Bendikson, Richard J Paulson.   

Abstract

OBJECTIVE: To estimate the current availability of donor cryopreserved oocytes and to describe the emerging phenomenon of commercial egg banks (CEBs) in the United States.
DESIGN: Cross-sectional survey of CEBs.
SETTING: E-mail, telephone, and fax survey of all CEB scientific directors, conducted April 2012. PATIENT(S): None. INTERVENTION(S): None. MAIN OUTCOME MEASURE(S): Number and location of CEBs in the United States, years in existence, number of donors, number of available oocytes, level of donor anonymity, donor screening, cost of oocytes to recipients, freezing/thawing technique, pregnancy statistics. RESULT(S): Seven CEBs were identified and surveyed (response rate: 100%). The CEBs used three distinct operational models, had been in existence for a median of 2 years (range: 1 to 8 years), with a median 21.5 (range: 6 to 100) donors and 120 (range: 20 to 1,000) currently available oocytes. The median recommended minimum number of eggs to obtain was six (range: four to seven), at an estimated mean cost per oocyte of $2,225 (range: $1,500 to $2,500). An estimated 3,130 oocytes from 294 donors are currently stored for future use. Of these CEBs, 6 (86%) of 7 use vitrification as cryopreservation method. To date, 8,780 frozen donor oocytes from CEBs have been used for in vitro fertilization, resulting in 602 pregnancies. Pregnancy rates per oocyte, available for 5 (71%) of 7 CEBs, were 532 (7.5%) of 7,080 for CEBs using vitrification and 70 (10%) of 700 for the single CEB using slow freezing as cryopreservation method. CONCLUSION(S): Frozen donor eggs are currently widely available in the United States. Three different operational models are currently used, resulting in more than 600 pregnancies from oocytes obtained at CEBs. The majority of CEBs use vitrification as cryopreservation technique.
Copyright © 2013 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 23200684     DOI: 10.1016/j.fertnstert.2012.10.047

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  7 in total

1.  The efficiency of a donor-recipient program using infertile donors' egg cryo-banking: a Brazilian reality.

Authors:  Rita de Cássia Sávio Figueira; Amanda S Setti; Daniela P A F Braga; Assumpto Iaconelli; Edson Borges
Journal:  J Assist Reprod Genet       Date:  2014-06-22       Impact factor: 3.412

2.  Oocyte vitrification: advances, progress and future goals.

Authors:  Ri-Cheng Chian; Yao Wang; Yi-Ran Li
Journal:  J Assist Reprod Genet       Date:  2014-01-30       Impact factor: 3.412

3.  Improved low-CPA vitrification of mouse oocytes using quartz microcapillary.

Authors:  Jung Kyu Choi; Haishui Huang; Xiaoming He
Journal:  Cryobiology       Date:  2015-04-11       Impact factor: 2.487

4.  Effect of oocyte donor stimulation on recipient outcomes: data from a US national donor oocyte bank.

Authors:  H S Hipp; A J Gaskins; Z P Nagy; S M Capelouto; D B Shapiro; J B Spencer
Journal:  Hum Reprod       Date:  2020-04-28       Impact factor: 6.918

5.  Association of Fresh Embryo Transfers Compared With Cryopreserved-Thawed Embryo Transfers With Live Birth Rate Among Women Undergoing Assisted Reproduction Using Freshly Retrieved Donor Oocytes.

Authors:  Iris G Insogna; Andrea Lanes; Malinda S Lee; Elizabeth S Ginsburg; Janis H Fox
Journal:  JAMA       Date:  2021-01-12       Impact factor: 56.272

6.  Racial and ethnic disparities among donor oocyte banks in the United States.

Authors:  Shelun Tsai; Esther H Chung; Tracy Truong; Amanda S Farrell; Jenny Wu; Onyinye Ohamadike; Jennifer L Eaton
Journal:  Fertil Steril       Date:  2022-01-17       Impact factor: 7.490

7.  Who benefits from putting family life into ice?

Authors:  Outi Hovatta
Journal:  Ups J Med Sci       Date:  2016-10-19       Impact factor: 2.384

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.